SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings is trending amid community excitement around a potential short squeeze, with traders actively discussing high short interest and a low float. The stock's price action and volume are fueling speculation about a significant upward move, with some comparing it to past high-flying stocks. Community members are also sharing information related to the company's new integrated energy strategy.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's performance post-earnings is sparking mixed reactions, with some questioning if the AI hype is sustainable as the stock struggles to hold gains despite positive results. The community is debating potential accounting issues and the concentration of revenue among a few key customers, while others see this as a temporary dip before a larger rally driven by long-term AI growth. Concerns about valuation, market manipulation, and broader economic headwinds are also fueling the discussion.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending due to rising memory chip prices driven by AI data center demand, with some analysts predicting substantial future growth and a new price target. Community discussions reflect bullish sentiment, but also caution about potential pullbacks after a significant year-to-date increase. Some traders point to technical indicators suggesting it may be overbought in the short-term.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to positive community sentiment fueled by strong earnings and a potential shift to a tech-forward image with a possible move to the Nasdaq. Discussions also revolve around the impact of consumer spending habits, SNAP benefits, and competition with other retailers. The stock is experiencing increased interest and mentions as a key player in the retail sector.

PACS Group, Inc. is a holding company, which engages in the provision of post-acute healthcare facilities, professionals, and ancillary services. It provides senior care, assisted living, and independent living options in some of the communities. The company was founded by Jason Murray and Mark Hancock in 2013 and is headquartered in Farmington, UT.

PACS Group Inc.

PACS Group is trending due to a short report alleging the company systematically scams taxpayer-funded healthcare programs, causing a significant stock drop and prompting community discussion about the validity of the claims and potential regulatory penalties. The conversation includes comparisons to other stocks targeted by short-sellers and speculation about the company's response. Some are anticipating a potential rebound or defense from the company, while others express concerns about the allegations and potential consequences.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as investors assess its potential following its recent IPO and subsequent price decline, with some seeing a buying opportunity amid broader market pressures. Community members are actively discussing the company's partnerships, particularly with Google, and its potential to disrupt the banking sector with its AI-driven approach. Despite the current negative price action, bullish sentiment remains, with some highlighting the company's growth potential and partnerships in the BNPL space.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending amid volatile crypto markets and a recent downturn, leading to heightened community discussion around unrealized losses and potential bottom prices. Investors are closely watching for a potential announcement regarding staking rewards to support the stock's price, while also debating the influence of analysts like Tom Lee and market factors on BMNR's performance in relation to Ethereum.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB is trending as the community speculates about a potential buyout, with many pointing to Nestle as a likely suitor given past collaborations and recent corporate restructuring. Discussions revolve around the timing of a deal before the end of the year, potential offer prices, and the impact on shareholders. Some traders are expressing skepticism, citing possible pump-and-dump schemes or an upcoming offering.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending due to discussions around its recent earnings, the acquisition of Chronosphere, and potential future M&A activity. While some investors are questioning the acquisition's price tag and its impact, others see it as a strategic move to solidify PANW's position as a comprehensive cybersecurity provider. Community members are actively debating the stock's valuation, growth prospects, and potential price targets.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community discusses potential government backing and regulatory developments related to deep sea mining. Chatter revolves around key individuals meeting in DC and speculation about upcoming announcements impacting permitting. Some traders are also noting high call option activity, while others express skepticism about the company's near-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The transaction, unanimously approved by both companies' boards of directors, is expected to close in the second quarter of 2026.</li><li>Once the deal is completed, Exact will operate as a unit of Abbott, and the latter’s total diagnostics sales will exceed $12 billion annually.</li><li>At the closing of the deal, Exact Sciences CEO Kevin Conroy will remain with the company in an advisory role.</li></ul>Abbott (ABT) on Thursday said it has entered into a definitive agreement to acquire Exact Sciences (EXAS) for up to $23 billion, as it seeks to expand into the cancer diagnostics segment.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments-302621643.html">deal</a>, Exact Sciences shareholders will receive $105 per common share in cash. This represents an upside of about 22% from the stock’s closing price on Wednesday.The transaction, unanimously approved by both companies' boards of directors, is expected to close in the second quarter of 2026, subject to the receipt of necessary approvals.<h2 class="st-heading-2">Upsides For Abbott</h2>Exact Sciences focuses on early cancer detection and on supporting personalized treatments. Its products include the Cologuard test, a noninvasive colorectal cancer screening option, and Cancerguard, a multi-cancer early detection blood test.Exact is expected to generate more than $3 billion in revenue this year, with a high-teens organic sales growth rate. Once the deal is completed, Exact will operate as a unit of Abbott, and the latter’s total diagnostics sales will exceed $12 billion annually, the companies said.At the closing of the deal, Exact Sciences CEO Kevin Conroy will remain with the company in an advisory role to support the transition, they added.<a href="https://stocktwits.com/symbol/ABT">Shares of Abbott </a>traded 0.6% lower on Thursday morning at the time of writing while <a href="https://stocktwits.com/symbol/EXAS">EXAS stock</a> rose 18%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EXAS jumped from ‘extremely bearish’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.EXAS stock is up by 81% this year and by about 93% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacs-group-stock-soars-premarket-on-completion-of-audit-commitee-probe-upbeat-full-year-guidance/cLPAjZFREa9">PACS Group Stock Soars Premarket On Completion Of Audit Committee Probe, Upbeat Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Exact Sciences logo of a molecular diagnostics company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Abbott To Acquire Exact Sciences For Up To $23B

PACS now expects core profit for the full year to be in the range of $480 million to $490 million, above an $472.72 million expected by analysts. 

Equity

Under the deal, Exact Sciences shareholders will receive $105 per common share in cash.


Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments Abbott to acquire Exact Sciences, a leader in large and fast-growing...

<ul class="summary-bullets"><li>Shares moved premarket as Wall Street highlighted that a potential Abbott deal would likely require a valuation well above prior estimates.</li><li>William Blair said even conservative modeling supports a takeover price far higher than Exact Sciences’ recent trading range.</li><li>The interest comes as Abbott reportedly explores a major acquisition to expand its diagnostics footprint.</li></ul>Exact Sciences Corp. shares slipped over 2% in pre-market trading on Thursday even as William Blair said a potential takeover by Abbott Laboratories would “likely” need to exceed $100 per share, based on what the firm called “very conservative assumptions.” The decline came despite reports that Abbott is reportedly nearing a deal to acquire the cancer-screening company.Exact Sciences surged 24% during Wednesday’s session, marking its biggest one-day gain in nearly 16 months. Meanwhile,&nbsp;Abbott’s&nbsp;stock fell nearly 3%.<h2 class="st-heading-2">William Blair Sees Takeout Well Above $80</h2>William Blair said that Exact Sciences currently trades at just under 5x forward sales, while an acquisition would likely require a 6x to 7x sales multiple, implying a premium of over 35%. The brokerage added that its September valuation analysis already showed a fundamental path to at least $80 per share.The firm argued that Abbott would need to offer “much more than this,” pointing to a price “likely over $100.” William Blair maintains ‘Outperform’ ratings on both Abbott and Exact Sciences.<h2 class="st-heading-2">Analysts See Abbott With Capacity To Strike A Blockbuster Deal</h2>Abbott is reportedly evaluating a transaction that would significantly expand its diagnostics franchise. The company has the capacity for as much as $30 billion in debt-funded M&amp;A, supported by roughly $7 billion in annual free cash flow, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-19/abbott-weighs-takeover-of-cancer-test-maker-exact-sciences">report</a>.Abbott’s diagnostics business was a major boost during the Covid-19 pandemic, but sales have since dwindled. The company has recently focused more on medical devices, with its glucose-monitoring products driving growth.<h2 class="st-heading-2">Cancer Screening Remains Exact Sciences’ Core Strength</h2>Exact Sciences’ flagship colorectal screening test, Cologuard, has been used more than 20 million times since 2014. The company employs more than 6,500 people and operates nine research and lab centers across the U.S., underscoring its scale within the precision-diagnostics landscape.<h2 class="st-heading-2">Stocktwits Users Push For Higher Bids</h2>On Stocktwits, Abbott saw ‘neutral’ sentiment on ‘normal’ message volume, while Exact Sciences drew ‘extremely bullish’ sentiment amid ‘extremely high’ volume.One user said, “If<a href="https://stocktwits.com/symbol/ABT"> $ABT</a> is serious, they need to offer 25-30 billion.<a href="https://stocktwits.com/symbol/EXAS"> $EXAS</a> Shouldn't sell for less.”<stembedurl>https://stocktwits.com/ABinterceptor/message/636831161</stembedurl>Another user said, “I dare another large diagnostics to start a bidding war. Where else can you get underpenetrated CRC market leader and MCED in the same market place? Another big player can bring in more salesforce and larger marketing budget to bring Cologuard 1.0 and 2.0 to the next level.”<stembedurl>https://stocktwits.com/Jasooon/message/636852465</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/EXAS">Exact Sciences’ stock</a> has risen 24% so far in 2025, Abbott’s stock has declined 3% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover

William Blair said even conservative modeling supports a takeover price far higher than Exact Sciences’ recent trading range.

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Vanguard Group Inc. Buys 2,977,715 Shares of Abbott Laboratories $ABT

Vanguard Group Inc. raised its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities...

BSX's Neuromodulation Prospect Looks Strong: What's Behind It?

Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.

Empowered Funds LLC Has $13.80 Million Stake in Abbott Laboratories $ABT

Empowered Funds LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 100.1% during the second quarter, according to its most recent Form 13F filing with the...

Abbott Laboratories $ABT Holdings Lowered by America First Investment Advisors LLC

America First Investment Advisors LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent...

Should You Continue to Hold Hologic Stock Post Q4 Earnings?

HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.

Abbott Laboratories $ABT Shares Bought by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 33.6% in the 2nd quarter, according to the company in its most recent filing with the...

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.50	--	--	N/A
Q3 '25	$1.30	$1.30	-0.19%	MISSED
Q2 '25	$1.25	$1.26	0.42%	BEAT
Q1 '25	$1.07	$1.09	1.66%	BEAT
Q4 '24	$1.33	$1.34	0.41%	BEAT

ABT
Abbott Laboratories

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ABT News

ABTAbbott Laboratories